Edwards Lifesciences (EW) Change in Receivables (2009 - 2026)

Edwards Lifesciences' Change in Receivables history runs 18 years deep, the most recent figure standing at $117.9 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 169.79% year-over-year to $117.9 million in Q1 2026; TTM through Mar 2026 was $97.2 million, a 173.36% increase from a year earlier, with the FY2025 full-year figure at $23.0 million, up 118.98% from the prior year.
• Change in Receivables grew to $117.9 million in Q1 2026 per EW's latest filing, from -$32.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $117.9 million in Q1 2026 and bottomed at -$105.9 million in Q4 2024.
• The 5-year median for Change in Receivables is $18.2 million (2023), against an average of $14.4 million.
• Across the five-year window, Change in Receivables jumped 1554.55% in 2023 and slumped 3538.46% in 2024, its largest moves.
• Year by year, Change in Receivables stood at $1.1 million in 2022, then jumped by 1554.55% to $18.2 million in 2023, then tumbled by 681.87% to -$105.9 million in 2024, then soared by 69.41% to -$32.4 million in 2025, then surged by 463.89% to $117.9 million in 2026.
• Per Business Quant, the three latest EW Change in Receivables figures stand at $117.9 million (Q1 2026), -$32.4 million (Q4 2025), and -$13.2 million (Q3 2025).